Although CD36 is weakly expressed in hepatocytes, it makes sense that accumulated lipid overload upregulates its expression, reinforcing clinical studies that have described a CD36 content increase in NAFLD patients (García-Monzón et al., 2014; Rada et al., 2020). Here, CD36 is linked to metabolic dysfunction-associated steatotic liver disease.